BioCentury
ARTICLE | Top Story

bluebird bio soars in trading debut

June 20, 2013 12:56 AM UTC

Gene therapy company bluebird bio Inc. (NASDAQ:BLUE) climbed $9.91 (58%) to $26.91 in its trading debut Wednesday. On Tuesday, the company raised $101 million through the sale of 5.9 million shares at $17 in an IPO, valuing bluebird at $387.8 million. With Wednesday's gains, the company is now valued at $613.8 million (see BioCentury Extra, June 18). ...